

Research Article

Open Access

# Human Leukocyte Antigen (HLA) Alleles Prevent Metabolically-Induced Inflammation and Cerebrocortical Thinning in Gulf War Illness

Peka Christova<sup>1,2</sup>, Lisa M. James<sup>1,2,3</sup>, Adam F. Carpenter<sup>1,4</sup>, Scott M. Lewis<sup>1,4</sup>, Brian E. Engdahl<sup>1,5</sup>, Apostolos P. Georgopoulos<sup>1,2,3,4\*</sup>

<sup>1</sup>Brain Sciences Center, Department of Veterans Affairs Health Care System, Minneapolis, MN, 55417, USA

<sup>2</sup>Department of Neuroscience, University of Minnesota Medical School, Minneapolis, MN 55455, USA

<sup>3</sup>Department of Psychiatry, University of Minnesota Medical School, Minneapolis, MN 55455, US

<sup>4</sup>Department of Neurology, University of Minnesota Medical School, Minneapolis, MN 55455, USA

<sup>5</sup>Department of Psychology, University of Minnesota Medical School, Minneapolis, MN 55455, USA

## Article Info

### Article Notes

Received: July 15, 2020

Accepted: August 20, 2020

### \*Correspondence:

Dr. Apostolos P. Georgopoulos, Brain Sciences Center (11B), Minneapolis VAHCS, One Veterans Drive, Minneapolis, MN 55417, USA; Email: omega@umn.edu.

© 2020 Georgopoulos AP. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License



### Keywords :

Gulf War Illness; Inflammation; Metabolic Human Leukocyte Antigen; Brain Atrophy Persistent Antigens

## ABSTRACT

Independent lines of research have demonstrated that GWI is associated with elevated inflammatory markers, metabolic disruptions, and alterations in brain morphometry. Possessing specific Class II human leukocyte antigen (HLA) alleles, on the other hand, has been shown to protect against GWI and to be inversely associated with symptom severity in a dose-dependent manner. The aim of the present study was to evaluate the association between C-reactive protein (CRP), a marker of inflammation, body mass index (BMI), and brain morphometry in GWI veterans with and without a protective HLA allele. Sixty-three veterans with GWI provided blood samples for evaluation of CRP and HLA, height and weight for calculating BMI, and underwent a 3T magnetic resonance imaging scan from which the volume, surface area, and cortical thickness of 68 cortical regions of interest (ROI) were determined. Results demonstrated that the CRP was highly significantly associated with BMI and cortical thinning in veterans lacking protective HLA alleles but not in those possessing a protective HLA allele. Given the role of HLA in antibody production against foreign antigens, the findings suggest that persistent foreign antigens stemming from lack of immunogenetic protection against them contribute to inflammation, metabolic disruption, and cortical thinning in GWI. The findings are discussed in terms of GW-related exposures that are known to result in inflammation.

## Introduction

Nearly thirty years after the 1990-1991 Persian Gulf War, Gulf War era veterans have continued to suffer from chronic, diffuse symptoms commonly referred to as Gulf War Illness (GWI)<sup>1,2</sup>. Although respiratory, gastrointestinal, and dermatological systems are involved in the GWI symptom constellation, most of the symptoms such as fatigue, pain, and neurological, cognitive and mood disruptions implicate primarily the central nervous system and the brain, in particular. Consequently, considerable research has investigated the nature and causes of brain abnormalities associated with GWI.

### GWI and brain atrophy

Numerous functional and structural brain abnormalities associated with GWI have been identified<sup>3,4</sup>. Among the most consistent findings regarding brain abnormalities has been evidence of brain atrophy in veterans with GWI<sup>5-12</sup>. We recently reported substantial (~10%) atrophy in veterans with GWI relative to healthy veterans<sup>5</sup>, in areas proximal to the most permeable regions of the blood brain barrier (BBB)<sup>13</sup>. Disruption of the BBB has been shown to be associated with atrophy in

an animal model of GWI in which rats were exposed to a combination of stress restraint and chemicals (nerve agent prophylactics and insecticides) that Gulf War veterans may have encountered in theater<sup>14</sup>. Brain morphology is likely to be compromised by a breakdown in BBB integrity resulting from chronic inflammation<sup>15-17</sup>, which is common in GWI.

### **GWI: Lack of immunogenetic protection**

Mounting evidence from human<sup>18-21</sup>, in vitro<sup>22-26</sup>, and in silico<sup>27</sup> studies implicates persistent antigens stemming from lack of immunogenetic protection in GWI and GW-associated inflammation. Specifically, six Class II human leukocyte antigens (HLA), which play an essential role in host protection via antibody production, have been shown to distinguish healthy GW veterans from those with GWI, and the number of these protective HLA alleles corresponds with GWI symptom severity in a dose dependent manner<sup>18</sup>. Furthermore, these protective HLA alleles have been shown to influence brain function in Gulf War veterans<sup>19</sup> and protect against brain atrophy<sup>21</sup> characteristic of veterans with GWI<sup>5</sup>. Given the instrumental role of Class II HLA in antibody production against foreign antigens via CD4+ T cells, these studies point to lack of immunogenetic protection against foreign antigens leading to antigen persistence and, consequently, inflammation in veterans with GWI<sup>18, 21</sup>. We have speculated that persistent foreign antigens from vaccines administered to Gulf War veterans lacking immunogenetic protection against them may underlie GWI. To that end, in vitro studies have demonstrated harmful effects of serum from GWI veterans on neural cultures that is ameliorated with serum from healthy Gulf War veterans<sup>22</sup>, pooled antibodies<sup>23</sup>, and antibodies against Gulf War vaccine antigens<sup>24-26</sup>.

### **GWI and inflammation**

Several studies have documented evidence of inflammation in veterans with GWI<sup>28-31</sup>. C-reactive protein (CRP), a non-specific biomarker of inflammation, has been shown to be elevated in GWI<sup>28-31</sup>, and has been implicated in GWI symptoms involving the brain, in particular<sup>28</sup>. Although historically viewed as a marker of inflammation that arises in response to inflammatory cytokines such as interleukin 6, evidence also suggests that CRP may also play a causal role in inflammation<sup>32</sup>. Thus, CRP may both signal and potentiate inflammation, thereby increasing BBB permeability. Indeed, systemic inflammation has been shown to predict BBB dysfunction<sup>33</sup>. Furthermore, inflammation has been intimately connected to metabolic disorders<sup>34</sup> which are common among Gulf War veterans<sup>35</sup>.

### **Systemic inflammation and neurodegeneration**

Considerable evidence suggests a robust association between CRP and chronic inflammatory and neurodegenerative conditions including cardiovascular disease, type 2 diabetes mellitus, age-related macular

degeneration, hemorrhagic stroke, Alzheimer's disease, and Parkinson's disease<sup>36</sup>. In addition, elevated CRP levels have been associated with brain atrophy even in healthy people<sup>37-41</sup>, highlighting the contribution of inflammatory markers on brain morphology independent of conditions that are typically associated with neurodegeneration. Although the mechanisms remain to be fully elucidated, there is evidence that CRP stimulates production of pro-apoptotic cytokines including interleukin-1 $\beta$  (IL-1 $\beta$ ), tumor necrosis factor- $\alpha$  (TNF $\alpha$ ), and reactive oxygen species<sup>32</sup>. Elevated peripheral inflammation has been associated with declines in cognitive function, an effect presumed to be mediated by the effect of inflammation on brain morphology<sup>39</sup>. BMI is also inherently related to inflammation because adipose tissues release inflammatory cytokines, which promote further metabolic disruptions in a vicious cycle<sup>34</sup>.

### **The current study**

Separate lines of research have demonstrated that GWI is associated with elevated CRP, metabolic conditions, and with brain atrophy, and that protection from GWI is conferred by presence of specific Class II HLA alleles. The aim of the present study was to evaluate the association between CRP, body mass index (BMI), and brain morphometry in veterans with GWI with regard to HLA. We have proposed that exposure to foreign antigens coupled with a genetic vulnerability that precludes their elimination results in persistent antigens and, ultimately, inflammation, cell damage, and atrophy<sup>18, 21, 42</sup>. Recent advances in morphometric analyses permit distillation of cortical volume into its component parts, surface area and cortical thickness, allowing for finer grain examination of the influence of inflammation on these two variables independently.

### **Materials and Methods**

#### **Participants**

Sixty-three veterans with GWI (59 men and 4 women; age  $55.2 \pm 1.1$  y, mean  $\pm$  SEM) gave informed consent to imaging acquisitions in accordance with the Declaration of Helsinki. GWI status was determined using a self-report symptom checklist that permits classification as GWI case or control according to the Center for Disease Control<sup>1</sup> and the Kansas criteria<sup>2</sup>, the case definitions recommended by the Institute of Medicine<sup>43</sup>. The Center for Disease Control definition requires one or more symptoms in at least two domains that include fatigue, pain, or mood and cognition. The more restrictive Kansas criteria requires that veterans report moderate to severe symptoms in at least 3 of 6 domains: fatigue, pain, neurological/cognitive/mood, skin, gastrointestinal, and respiratory. All GWI veterans in the present study met both case definitions. Consistent with the Kansas criteria case definition, none of the participants

had co-occurring medical or psychiatric conditions that could account for GWI symptoms or impair reporting<sup>2</sup>, including veterans with schizophrenia, bipolar disorder, drug abuse or alcoholism, neurological conditions and inflammatory rheumatological conditions. Individuals with traumatic brain injury were also excluded from the study. The study was approved by the University of Minnesota and Minneapolis VA Health Care System Institutional Review Boards.

### Body Mass Index (BMI)

BMI was computed using the height and weight of the participant ( $BMI = kg/m^2$ ).

### CRP

Non-fasting peripheral venous blood samples were collected for evaluation of high sensitivity C reactive protein and analyzed using standard procedures by the Minneapolis VAHCS Clinical Laboratory.

### HLA Genotyping

DNA isolation was carried out from 3 ml of whole blood drawn in EDTA tubes, using a commercially available kit (ArchivePure cat. 2300730) from 5Prime (distributed by Fisher Scientific or VWR) with an expected yield of 50-150 $\mu$ g of DNA. The purified DNA samples were sent to Histogenetics (<http://www.histogenetics.com/>) for high-resolution HLA Sequence-based Typing (SBT; details are given in <https://bioinformatics.bethematchclinical.org/HLA-Resources/HLA-Typing/High-Resolution-Typing-Procedures/> and <https://bioinformatics.bethematchclinical.org/WorkArea/DownloadAsset.aspx?id=6482>). Their sequencing DNA templates are produced by locus- and group-specific amplifications that include exon 2 and 3 for class I (A, B, C) and exon 2 for class II (DRB1, DRB3/4/5, DQB1, and DPB1) and reported as Antigen Recognition Site (ARS) alleles as per ASHI recommendation<sup>44</sup>.

### Magnetic Resonance Imaging (MRI) acquisition

All data were acquired using a Philips 3T MR scanner (Achieva, Philips Healthcare, Best, The Netherlands). In the initial phase of the study, data were acquired from 18 participants using a phased array SENSitivity Encoding (SENSE) 8-channel head coil for reception. For each participant a high resolution T1-weighted Turbo Field Echo (T1w TFE SENSE) was obtained (168 sagittal slices, TR = 8.1932 ms, TE = 3.7520 ms, Acquisition matrix 240 × 240, Flip angle 8 deg., voxel size 0.9375 × 0.9375 × 1 mm). A T2-weighted image (T2w VISTA HR SENSE) was also obtained (180 slices, TR = 2500 ms, TE = 363.072 ms, Acquisition matrix 252 × 252, voxel size = 0.7813 × 0.7813 × 1 mm). Subsequently, upgrades were applied to the system and data were acquired from the remainder 45 participants using a phased array SENSitivity Encoding (SENSE)

15-channel head coil for reception. For each participant a high resolution T1-weighted Turbo Field Echo (T1w TFE SENSE) was obtained (168 sagittal slices, TR = 8.0928 ms, TE = 3.698 ms, Acquisition matrix 240 × 240, Flip angle 8 deg., voxel size 0.7500 × 0.7500 × 1 mm). The T2-weighted (T2w VISTA HR SENSE) was also obtained (168 slices, TR = 2500 ms, TE = 370.346 ms, Acquisition matrix 240 × 240, voxel size = 0.7500 × 0.7500 × 1 mm).

### MRI image processing

Data were processed by a 704-core High Performance Computing system (CentOS 6.5 Linux, Rocks 6.1.1), Matlab R2016 (64 bit), and the Human Connectome Project (HCP; [humanconnectome.org](http://humanconnectome.org)) pipeline, including the FreeSurfer (FS; <http://surfer.nmr.mgh.harvard.edu>) HCP version. Full details were presented previously<sup>5</sup>. Briefly, we used a modified version of FS, implemented in the structural HCP pipeline, which utilizes both T1-w and T2-w images to eliminate uncertainty and improve surface reconstruction<sup>45</sup>.

FS, a widely used tool, provides reliable brain measurements validated by manual<sup>46, 47</sup> and histological analysis<sup>48</sup>. FS's surface-based stream reconstructs the cortical surface by using models of the boundary between the white and gray matter and between the gray matter and cerebrospinal fluid (this is the pial surface)<sup>49-51</sup>. This algorithm uses intensity and continuity information to generate a continuous cortical ribbon, and creates a mesh of hundreds of thousands of triangles that recover the geometry and the topology of the pial surface and gray/white boundary. Cortical thickness is calculated as the closest distance from the gray/white boundary and pial surface at each vertex on the tessellated surface in both hemispheres<sup>52</sup>. The FS procedure allows submillimeter resolution that is higher than the voxel resolution of the original data. The cortical ribbon is then parcellated into regions of interests (ROIs) based on gyral and sulcal structures of the Desikan-Killiany atlas<sup>53</sup>. Each resulting image was visually inspected for inaccuracy. Mean thickness, cortical volume, and surface area were extracted for each brain ROI from each individual participant's brain image.

### Brain areas

The volumes, surface area and thickness of 68 cerebrocortical Regions of Interest (ROIs; 34 left and 34 right) were analyzed. Their names are given in the Appendix.

### Data analysis


For each brain, 68 ROIs × 3 measures (surface, thickness, volume) = 204 values were available, for a total of 63 brains × 204 values/brain = 12852 data values; namely, 4284 values per measure above. For specific groups, N = 68 ROIs × 41 HLA-p0 brains = 2788 values, and N = 68 ROIs

x 22 HLA-p1 brains = 1496 values. In addition, for each participant, the following data were available: gender, age, HLA group (presence or absence of a GWI protective allele), BMI, and CRP. CRP values were skewed to the right and were (natural) log-transformed to normalize their distribution<sup>28</sup>. Standard statistical methods were used to analyze the data, including t-test, Fisher's exact test for 2x2 tables, and partial correlation analyses. All statistical analyses were done using the IBM-SPSS statistical package (version 23).

## Results

### General

Of the 63 participants, 41 (HLA-p0 group) lacked all of the 6 GWI protective alleles (DRB1\*01:01, DRB1\*08:11, DRB1\*13:02, DQB1\*02:02, DPB1\*01:01, DPB\*06:01)<sup>18</sup>, whereas 22 participants (HLA-p1 group) carried one such allele (12 carried DRB1\*01:01, 4 DRB1\*13:02, 2 DQB1\*02:02, 4 DPB1\*01:01).



**Figure 1.** Frequency distribution of BMI for the two HLA groups. (See text for details.)

### MRI Acquisition

As mentioned in the Methods above, there were two kinds of MRI acquisitions, one using an 8-channel system and the other a 15-channel system. Participants were distributed similarly. In the HLA-p0 group, 13 and 28 participants were imaged with the 8- and 15-channel equipment, respectively, whereas in the HLA-p1 group those counts were 5 and 17, respectively; there was no significant association between the HLA groups and the MRI method of acquisition ( $P = 0.564$ , Fisher's exact test for the 2x2 table).

### Comparisons of non-neural measures between the 2 HLA groups


**Gender.** The HLA-p0 group comprised 37 men and 4 women, whereas the HLA-p1 group comprised 22 men; the two groups did not differ significantly with respect to the gender composition ( $P = 0.288$ , Fisher's exact test for the 2x2 table).

**Age.** The mean  $\pm$  SEM age for the HLA-p0 group was  $54.9 \pm 1.5$  y, and that for the HLA-p1 group was  $55.8 \pm 1.6$ . These means did not differ significantly (t-test,  $t_{[61]} = 0.378$ ,  $P = 0.707$ ).



**BMI** (Figure 1). The mean  $\pm$  SEM BMI for the HLA-p0 group was  $31.5 \pm 0.82$ , and that for the HLA-p1 group was  $31.0 \pm 1.02$ . These means did not differ significantly (t-test,  $t_{[61]} = 0.357$ ,  $P = 0.722$ ).

**CRP** (Figure 2). CRP was appreciably lower in the HLA-p1 group but the difference did not reach statistical significance: The mean  $\pm$  SEM  $\ln(\text{CRP})$  for the HLA-p0 group was  $0.81 \pm 0.15$ , and that for the HLA-p1 group was  $0.44 \pm 0.20$ . These means did not differ significantly (t-test,  $t_{[61]} = 1.46$ ,  $P = 0.149$ ).

**Association of CRP and BMI** (Figure 3). In the HLA-p0 group,  $\ln(\text{CRP})$  was positively and significantly correlated with BMI ( $r = 0.409$ ,  $P = 0.006$ ,  $N = 41$ ). In contrast, there



**Figure 2.** Frequency distribution of CRP and  $\ln(\text{CRP})$  for the two HLA groups. (See text for details.)



was no significant correlation in the HLA-p1 group ( $P = 0.309$ ).

### Comparisons of association of CRP with neural measures between the 2 HLA groups

The association of CRP with neural measures (cortical volume, surface and thickness) was evaluated by computing the partial correlation coefficient between ln(CRP) and each measure above, controlling for estimated total intracranial volume (eTIV), age and gender, as needed (e.g. gender was entered as covariate only for the HLA-p0 group, since the HLA-p1 group comprised only men). We found the following.

*Association of CRP with cortical volume.* No statistically significant partial correlations ( $r_p$ ) were found between ln(CRP) and cortical volume in either HLA group

(HLA-p0, controlling for age, gender, and eTIV:  $r_p = -0.009$ ,  $P = 0.645$ ,  $DF = 2783$ ; HLA-p1, controlling for age and eTIV:  $r_p = -0.009$ ,  $P = 0.722$ ,  $DF = 1492$ ).

*Association of CRP with cortical surface.* No statistically significant partial correlations were found between ln(CRP) and cortical surface in either HLA group (HLA-p0, controlling for age, gender, and eTIV:  $r_p = -0.002$ ,  $P = 0.903$ ,  $DF = 2783$ ; HLA-p1, controlling for age and eTIV:  $r_p = -0.018$ ,  $P = 0.405$ ,  $DF = 1492$ ).

*Association of CRP with cortical thickness (CT)* (Figure 4). A highly statistically significant partial correlation was found between ln(CRP) and cortical thickness in the HLA-p0 group ( $r_p = -0.063$ ,  $P = 0.00092$ ,  $DF = 2783$ , controlling for age, gender, and eTIV). In contrast, no significant partial correlation was found for the HLA-p1 group ( $r_p = 0.045$ ,  $P = 0.081$ ,  $DF = 1492$ , controlling for age and eTIV; notice the positive correlation). A more detailed examination of the ln(CRP) vs. thickness relation in the HLA-p0 group revealed that a better fit was a power fit, i.e. a linear relation in a log-log scale. This makes sense, since it implies that even very high levels of CRP will never result in zero thickness. The results for the log-log relation were:  $r_p = -0.07$ ,  $P = 0.000208$ ,  $DF = 2783$ , controlling for age, gender, and eTIV). The association of cortical thickness (lnCT) and CRP (lnCRP) remained significant after accounting for BMI ( $r_p = -0.069$ ,  $P = 0.000284$ ,  $DF = 2782$ , controlling for BMI, age, gender, and eTIV). BMI was not significantly associated with cortical thickness in either group (HLA-p0 group:  $r = -0.023$ ,  $P = 0.215$ ,  $N = 2788$ ; HLA-p1 group:  $r = -0.037$ ,  $P = 0.157$ ,  $N = 1496$ ).

*Comparison of cortical thickness between the two HLA groups.* Cortical thickness, adjusted for age, gender, eTIV, and ln(CRP) was overall higher in the HLA-p1 than the HLA-p0 group but this difference did not reach statistical significance; the mean ± SEM of ln(CT) for the HLA-p0 group was  $0.911 \pm 0.003$ ,  $N = 41$ , and for the HLA-p1 group  $0.916 \pm 0.005$ ,  $N = 22$ ;  $P = 0.346$ ).

## Discussion

Here we investigated the effect of GWI-protective HLA alleles on the association between inflammation, BMI, and brain morphometry in veterans with GWI. The results demonstrated a highly significant association between CRP with BMI and cortical thickness, but not surface area or cortical volume, in GWI veterans lacking one of the protective Class II HLA alleles. There were no such associations in veterans possessing one of the protective alleles. These findings suggest that persistent antigens stemming from lack of HLA protection influence metabolic and inflammatory systems, contributing to cortical thinning. These results add to the literature highlighting the role of inflammation in GWI, narrow the focus of GWI risk factors to those that are known to contribute to inflammation, and point towards potential treatment avenues aimed at reducing inflammation. We discuss below GW-related exposures, highlighting the potential role of persistent antigens on GWI inflammation.

### Differential Associations of CRP on Brain Morphometry

Several studies have documented morphometric alterations associated with GWI including reduced brain volume<sup>4, 5</sup>. Here we focused on the cerebral cortex, analyzing its volume, surface area, and thickness. The current study documents the association between CRP and reduced cortical thickness in GWI veterans lacking protective HLA alleles, but no association with surface area or cortical volume. This dissociation of effects is consistent with findings that changes in cortical gray matter volume are almost exclusively driven by changes in surface area<sup>54, 55</sup>, and that surface area and volume are underlain by distinct genetic influences<sup>56</sup> and reflect different aspects of brain architecture and distinct cellular mechanisms<sup>55</sup>. In addition, cortical thickness and surface area are negatively correlated<sup>57</sup>. Cortical thickness is a more sensitive measure of gray matter alteration than volume<sup>58</sup>, and many neurological and psychiatric conditions are associated with variations in cortical thinning<sup>59-64</sup>, leading some to suggest cortical thickness is a candidate biomarker for differential diagnosis and disease prognosis<sup>65</sup>. The current study provides evidence of cortical thinning in veterans with GWI who lack immunogenetic protection; longitudinal studies are warranted to examine the association of cortical thickness with GWI disease prognosis.

### Metabolic and Immune System Interactions and Cortical Thinning

Considerable research highlights a robust association between the immune and metabolic systems such that inflammation is unequivocally causally associated with metabolic system disruptions which promote further inflammation<sup>34</sup>. Indeed, the association between

inflammation and obesity has been referred to as a “chicken or the egg” question as activation of the immune system can promote weight gain and obesity, and obesity can perpetuate inflammation<sup>34</sup>. Furthermore, CRP and BMI have each been linked to reduced cortical thickness<sup>66, 67</sup>, as has expression of genes specific to astrocytes and microglia, the brain’s resident immune cells<sup>68</sup>. Here, CRP, a marker of inflammation, was highly significantly associated with BMI and cortical thinning, but only in veterans lacking a protective HLA allele; BMI was not associated with cortical thinning in either group. This suggests that persistent antigens resulting from lack of immunogenetic protection against them may contribute to both inflammation and obesity, the latter of which may promote additional inflammation. In contrast, there were no significant associations between CRP, BMI, and cortical thickness in GWI veterans possessing 1 protective HLA allele. Taken together, these findings raise the possibility of at least two inflammatory drivers in GWI – one stemming from persistent antigens and a separate mechanism that includes metabolically-induced inflammation. It also raises the possibility that the varied symptoms associated with GWI may be partially attributable to differences in HLA composition. For example, cognitive symptoms may be more prominent in those lacking HLA protection due to reduced cortical thickness stemming from persistent antigens. Next, we discuss environmental exposures that may contribute to antigen persistence in GWI, highlighting the role of vaccines.

### In-theater exposure and GWI

GWI is typically attributed to deployment-related exposures either alone or in combination with psychological stress or other exposures. Commonly investigated in-theater exposures includes chemical nerve agents (e.g., sarin) and widespread use of pyridostigmine bromide (PB) to protect against possible nerve agent attacks, frequent use of pesticides, and airborne contaminants from oil well fires. While implicating in-theater exposures has provided convenient explanations for the excess symptomatology seen in GWI veterans, relative to non-deployed GW veterans or those deployed to other regions, the lack of documentation on actual in-theater exposures limits causal connections regarding exposure to any specific agent and GWI. Furthermore, despite decades of study it remains unclear how exposure to such toxicants could contribute to GWI symptoms 30 years later. Take, for instance, sarin. A number of military personnel were exposed to low-level sarin following the destruction of an Iraqi ammunition dump, in Khamisiyah, Iraq. Although sarin is extremely toxic, it is short-lived inside the body where it is quickly metabolized and excreted through urine. Thus, while some deleterious effects may be expected following sarin (and other toxicant exposure), it is unclear how sarin could contribute to progressive effects nearly 30 years later given the rapid metabolism and short half-life. A condition known as organophosphate-induced

chronic neurotoxicity (OPICN) has been described in the literature, and is characterized by neuropathological, neurological, neuropsychological, and neurobehavioral alterations as a result of a large single exposure or repeated small sarin exposures<sup>69</sup>. Notably, the characteristics are similar to those seen in GWI and some have considered OPICN as a possible explanation for GWI<sup>70</sup>. OPICN may indeed be related to GWI, particularly the excess of GWI seen in deployed veterans relative to their non-deployed and other-deployed counterparts; however, to date, the mechanisms of OPICN progressive effects remain unclear<sup>71</sup> and the contribution of sarin and other nerve agents to GWI is largely inconclusive. Others have concluded that pesticides and/or PB are causally associated with GWI<sup>4, 72</sup>. Similar to nerve agent exposure, use of pesticides and PB may play a contributory role in GWI symptomatology; however, neither OPICN, pesticides, nor use of PB can account for GWI cases observed in non-deployed veterans. It is notable that up to 36% of veterans who never deployed (depending on which GWI case definition was used) report GWI-consistent symptom profiles<sup>4, 72</sup>, suggesting that the constellation of symptoms referred to as GWI cannot be solely attributable to in-theater exposure.

## Vaccines and GWI

Both deployed and non-deployed GW veterans received multiple vaccinations in preparation for the war and those vaccines have become another widely investigated risk factor for GWI. Reports indicate that new recruits during the GW era received up to 17 vaccines during the first two weeks of basic training<sup>72</sup>. Several studies have concluded that vaccinations are associated with GWI, and have documented evidence of GWI in non-deployed GW veterans and in other-deployed veterans who received vaccines, albeit at lower rates than deployed GW veterans<sup>2, 73, 74</sup>. Furthermore, a dose-response relationship has been reported between the number of vaccines and severity of health symptoms<sup>31</sup>. In addition to standard vaccines (e.g., yellow fever, cholera, hepatitis B, etc.), the Gulf War was the first time that a large number of military personnel (150,000 deployed and non-deployed veterans) received the anthrax vaccine, the safety of which has been called into question<sup>75</sup>. As Nass<sup>75</sup> discusses, an unusually high rate of adverse events was reported for anthrax vaccine relative to other vaccines, with vaccine recipients developing at least 2 of the following 3 symptoms: fatigue, muscle or joint pains, and cognitive or emotional impairment, symptoms consistent with the CDC case definition of GWI<sup>1</sup>. Nass<sup>75</sup> concludes that statements that existing scientific evidence does not support an association between anthrax vaccine and GWI are simply not true. Indeed, given the incidence of GWI in non-deployed veterans who received preparatory vaccinations, it seems quite likely that anthrax and potentially one or more of the 17 antigens administered

are implicated in GWI. To that end, recent in vitro studies have documented deleterious effects of GWI serum on cell cultures and reversal of those effects with the concomitant addition of antibodies against antigens contained in the vaccines administered to GW veterans<sup>24-26</sup>.

## Vaccines, Persistent Antigens, and Inflammation

In discussing the role of vaccines in GWI, the Institute of Medicine<sup>76</sup> noted that adverse effects of vaccinations could be due to the toxicity of the antigen in the vaccine and/or from stimulation of the immune system (the intended goal of immunization) that may result in immune enhancement, hypersensitivity, or an immune-mediated pathological response. They continue to describe acute effects (e.g., rash) as well as sustained effects including tissue damage due to inflammation that tends to be seen in the lung, kidney, joints, and brain in animal studies.

Finally, the IOM report notes that genetic inheritance strongly influences the immune response to immunization and to actual infection, and explains the high variability in response to vaccinations. HLA genes, in particular, are highly related to immune response. Antibody production hinges on a match between epitopes derived from an antigen and an individual's HLA profile. In the absence of an HLA-antigen match, the antigen persists<sup>21, 42</sup>, contributing to inflammation and ultimately tissue damage. As previously mentioned, there is mounting evidence documenting inflammation in veterans with GWI<sup>28-31</sup>. Furthermore, we identified 6 HLA alleles that were present in healthy GW veterans but were absent or significantly less frequent in those with GWI, indicating that GWI is associated with genetic lack of protection<sup>18</sup>. Thus, we suspect that GWI is a result of persistent antigens that could not be eliminated due to HLA-antigen incongruence, resulting in inflammation and ultimately neurodegeneration. Notably, HLA variability has been specifically implicated in regards to variability in antibody production to anthrax vaccine<sup>77</sup>. Similarly, in silico analyses highlight variability in the binding affinity of GWI vaccine antigens to protective HLA, thereby differentially affecting antibody production<sup>27</sup>.

We have studies underway aimed at identifying persistent antigens in veterans with GWI with the goal of ultimately eliminating them (thereby reducing inflammation and slowing progression of cortical thinning) via personalized immunotherapy. Findings from two recent in vitro studies in our lab demonstrated that serum from veterans with GWI results in detrimental changes to cell morphology in neural cultures; however, the damaging effects were neutralized with the addition of serum from healthy Gulf War veterans<sup>22</sup> or human immunoglobulin G<sup>23</sup>. Consistent with the Persistent Antigen hypothesis<sup>21, 42</sup>, the neutralizing effects are presumably due to ability of antibodies present in serum from healthy Gulf War veterans and in pooled

IgG to eliminate persistent antigens in veterans with GWI. Subsequent *in vitro* studies have documented evidence of adverse of GWI serum on cell cultures and reversal of those effects with the concomitant addition of antibodies against antigens contained in the vaccines administered to GW veterans<sup>24-26</sup>. Taken together, these findings highlight the fact that harmful persistent antigens circulating in the blood partly contribute to inflammation and ultimately cortical thinning in GWI. We anticipate that elimination of persistent antigens would reduce those effects.

### Limitations

The findings from the present study must be considered in light of limitations. First, a small number of HLA alleles were investigated in the present study; thus, the effects of other HLA alleles on metabolically-induced inflammation and cerebrocortical thinning are unknown. The six Class II HLA alleles investigated here were identified from among 144 Class I and Class II alleles in a prior study of GWI<sup>18</sup>. These six alleles were shown to discriminate veterans from GWI from healthy GW controls, and exhibited a dose-dependent relationship with GWI symptoms such that fewer protective alleles were associated with more GWI symptoms. Other alleles did not confer that protection and are, therefore, considered non-protective. Subsequent studies have demonstrated various protective effects of these alleles as it relates to GWI<sup>19-27</sup>. This study extends those findings to demonstrate additional protection of these six Class II HLA alleles on metabolically-induced inflammation and cerebrocortical thinning. Second, the veterans in the present study had elevated BMI which is known to be associated with inflammation via release of cytokines<sup>34, 78, 79</sup>; however, there were no difference in BMI between veterans with and without protective alleles, and BMI did not account for the observed association between CRP and cerebrocortical thinning in veterans without protective HLA alleles. There is the possibility that this group of GW veterans with elevated BMI are not representative of GWI veterans in general although that is unlikely given that several other studies of Gulf War veterans have similarly found elevated BMI<sup>30, 31, 80, 81</sup>. Finally, the study sample was relatively small. Future studies with larger samples are warranted to corroborate the findings and evaluate generalizability to the broader GWI population.

### Conclusion

In the present study we demonstrated that inflammation is highly associated with BMI and cortical thinning in veterans with GWI who lack protective HLA alleles, but not in those who possess a GWI-protective HLA allele. These findings suggest that inflammation due to the persistence of foreign (potentially vaccine-related) antigens resulting from lack of HLA protection contributes to GWI. Future studies aimed at eliminating persistent antigens may be

effective in reducing the varied symptoms associated with GWI, particularly those involving the brain.

### Acknowledgements

This work was partially supported by the Department of Defense (Award Number W81XWH-15-1-0520), University of Minnesota (the American Legion Brain Sciences Chair) and the U.S. Department of Veterans Affairs. The sponsors had no role in the current study design, analysis or interpretation, or in the writing of this paper. The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government.

### Author Contributions

Contributed to data collection: LMJ, AFC, SML. Contributed to participant recruitment and evaluation: BEE, LMJ. Contributed to study design: APG, BEE, LMJ, AFC. Contributed to data analysis: APG, PC. Wrote the paper: LMJ, PC, APG. Contributed to editing the paper: All.

### Conflicts of Interest

None

### References

1. Fukuda K, Nisenbaum R, Stewart G, et al. Chronic multisymptom illness affecting Air Force veterans of the Gulf War. *JAMA*. 1998; 280(11): 981-988. doi: 10.1001/jama.280.11.981
2. Steele L. Prevalence and patterns of Gulf War illness in Kansas veterans: association of symptoms with characteristics of person, place, and time of military service *Am J Epidemiol*. 2000; 152: 992-1002. doi: 10.1093/aje/152.10.992
3. Engdahl BE, James LM, Miller RD, et al. A magnetoencephalographic (MEG) study of Gulf War Illness (GWI). *EBioMedicine*. 2016; 12: 127-32. doi: 10.1016/j.ebiom.2016.08.030
4. White RF, Steele L, O'Callaghan JP, et al. Recent research on Gulf War illness and other health problems in veterans of the 1991 Gulf War: effects of toxicant exposures during deployment. *Cortex*. 2016; 74: 449-475. doi: 10.1016/j.cortex.2015.08.022
5. Christova P, James LM, Engdahl BE, et al. Subcortical brain atrophy in Gulf War Illness. *Exp Brain Res*. 2017; 235: 2777-2786. doi: 10.1007/s00221-017-5010-8
6. Haley RW, Spence JS, Carmack PS, et al. Abnormal brain response to cholinergic challenge in chronic encephalopathy from the 1991 Gulf War. *Psychiatry Res*. 2009; 171(3): 207-220. doi: 10.1016/j.psychres.2008.05.004
7. Calley CS, Kraut MA, Spence JS, et al. The neuroanatomic correlates of semantic memory deficits in patients with Gulf War illnesses: a pilot study. *Brain Imaging Behav*. 2010; 4: 248-255. doi: 10.1007/s11682-010-9103-2
8. Chao LL, Abadjian L, Hlavin J, et al. Effects of low-level sarin and cyclosarin exposure and Gulf War Illness on brain structure and function: a study at 4T. *Neurotoxicology*. 2011; 32(6): 814-822. doi: 10.1016/j.neuro.2011.06.006
9. Chao LL, Rothlind JC, Cardenas VA, et al. Effects of low-level exposure to sarin and cyclosarin during the 1991 Gulf War on brain function and brain structure in US veterans *Neurotoxicology*. 2010; 31(5): 493-501. doi: 10.1016/j.neuro.2010.05.00
10. Li X, Spence JS, Buhner DM, et al. Hippocampal dysfunction in Gulf

- War veterans: investigation with ASL perfusion MR imaging and physostigmine challenge. *Radiology*. 2011; 261(1): 218–225. doi: 10.1148/radiol.11101715
11. Rosenzweig I, Bodi I, Nashef L. Comorbid multiple sclerosis and TDP-43 proteinopathy in a gulf war sea captain. *J Neuropsychiat Clin Neurosci*. 2012; 24: E41–E42. doi: 10.1176/appi.neuropsych.11030066
12. Rayhan RU, Stevens BW, Raksit MP, et al. Exercise challenge in Gulf War Illness reveals two subgroups with altered brain structure and function. *PLoS One*. 2013; 8(6): e63903. doi: 10.1371/journal.pone.0063903
13. Belova I, Jonsson G. Blood-brain barrier permeability and immobilization stress. *Acta Physiol Scand*. 1982; 116: 1-9. doi: 10.1111/j.1748-1716.1982.tb10594.x
14. Abdel-Rahman A, Shetty AK, Abou-Donia MB. Disruption of the blood-brain barrier and neuronal cell death in cingulate cortex, dentate gyrus, thalamus, and hypothalamus in a rat model of Gulf-War syndrome. *Neurobiol Dis*. 2002; 10(3): 306–326. doi: 10.1006/nbdi.2002.0524
15. Almutairi MM, Gong C, Xu YG, et al. Factors controlling permeability of the blood-brain barrier. *Cell Molec Life Sci*. 2016; 73(1): 57-77. doi: 10.1007/s00018-015-2050-8
16. Erickson MA, Dohi K, Banks WA. Neuroinflammation: a common pathway in CNS diseases as mediated at the blood-brain barrier. *Neuroimmunomodulation*. 2012; 19(2), 121-30. doi: 10.1159/000330247
17. Varatharaj A, Galea I. The blood-brain barrier in systemic inflammation. *Brain Behav Immun*. 2017; 60: 1-12. doi: 10.1016/j.bbi.2016.03.010
18. Georgopoulos AP, James LM, Mahan MY, et al. Reduced Human Leukocyte Antigen (HLA) protection in Gulf War Illness (GWI). *EBioMedicine*. 2016; 3: 79-85. doi: 10.1016/j.ebiom.2015.11.037
19. James LM, Engdahl BE, Leuthold AC, et al. Brain correlates of human leukocyte antigen (HLA) protection in Gulf War Illness (GWI). *EBioMedicine*. 2016; 13: 72–79. doi: 10.1016/j.ebiom.2016.10.019
20. Georgopoulos AP, James LM, Carpenter AF, et al. Gulf War illness (GWI) as a neuroimmune disease. *Exp Brain Res*. 2017; 235(10): 3217-3225. doi: 10.1007/s00221-017-5050-0.
21. James LM, Christova P, Engdahl BE, et al. Human leukocyte antigen (HLA) and Gulf War Illness (GWI): HLA-DRB1\*13:02 spares subcortical atrophy in Gulf War veterans. *EBioMedicine*. 2017; 26: 126-131. doi: 10.1016/j.ebiom.2017.11.005
22. Georgopoulos AP, Tsilibary EP, Souto EP, et al. Adverse effects of Gulf War Illness (GWI) serum on neural cultures and their prevention by healthy serum. *J Neurol Neuromed*. 2018; 3(2): 19-27. doi: 10.29245/2572.942X/2018/2.1177
23. Tsilibary EPC, Souto EP, James LM, et al. Human immunoglobulin G (IgG) neutralizes adverse effects of Gulf War Illness (GWI) serum in neural cultures: Paving the way to immunotherapy for GWI. *J Neurol Neuromed*. 2018; 3(5): 23-28. doi: 10.29245/2572.942X/2018/5.1219
24. Tsilibary EPC, Souto EP, Kratzke M, et al. Anthrax and Gulf War Illness (GWI): Evidence for the presence of harmful anthrax antigen PA63 in the serum of veterans with GWI. *J Neurol Neuromed*. 2019; 4(6): 1-9. doi: 10.29245/2572.942X/2019/6.1255
25. Tsilibary EPC, Souto EP, Kratzke M, et al. Anthrax protective antigen 63 (PA63): Toxic effects in neural cultures and role in Gulf War Illness (GWI). *Neuroscience Insights* (Accepted for publication).
26. Tsilibary EPC, Souto EP, Kratzke M, et al. Vaccine-induced adverse effects in cultured neuroblastoma 2A (N2A) cells duplicate toxicity of serum from patients with Gulf War Illness (GWI) and are prevented in the presence of specific anti-vaccine antibodies. *Vaccines*. 2020; 8: 232. 27. doi: 10.3390/vaccines8020232
27. Charonis S, James LM, Georgopoulos AP. In silico analysis of the binding affinities of antigenic epitopes of vaccines administered to Gulf War Veterans to specific HLA Class II alleles protective for Gulf War Illness. *J Neurol Neuromed*. 2019; 4(5): 23-30. doi: 10.29245/2572.942X/2019/5.1254
28. James LM, Engdahl BE, Johnson RA, et al. Gulf War Illness and inflammation: Association of symptom severity with C-reactive protein. *J Neurol Neuromed*. 2019; 4(2): 15-9. doi: 10.29245/2572.942X/2019/2.1245
29. Johnson GJ, Leis LA, Slater BC, et al. Elevated platelet count, C-reactive protein and thromboxane analog-induced platelet aggregation in patients with Gulf War veterans' illnesses: evidence of a chronic inflammatory state? *Blood Coagul Fibrinolysis*. 2013; 24: 736–741. doi: 10.1097/MBC.0b013e328362627f.
30. Johnson GJ, Slater BC, Leis LA, et al. Blood biomarkers of chronic inflammation in Gulf War Illness. *PLoS One*. 2016; 11(6): e0157855. doi: 10.1371/journal.pone.0157855
31. Kelsall HL, McKenzie DP, Sim MR, et al. Physical, psychological, and functional comorbidities of multisymptom illness in Australian male veterans of the 1991 Gulf War. *Am J Epidemiol*. 2009; 170: 1048–1056. doi: 10.1093/aje/kwp238
32. Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. *Frontiers Immunol*. 2018; 9: 754. doi: 10.3389/fimmu.2018.00754
33. Elwood E, Lim Z, Naveed H, et al. The effect of systemic inflammation on human brain barrier function. *Brain Behav Immun*. 2017; 62: 35–40. doi: 10.1016/j.bbi.2016.10.020
34. Hotamisligil GS. Inflammation and metabolic disorders. *Nature*. 2006; 444: 860-7. doi: 10.1038/nature05485
35. Blanchard MS, Eisen SA, Alpern R, et al. Chronic multisymptom illness complex in Gulf War I veterans 10 years later. *Am J Epidemiol*. 2006; 163: 66-75. doi: 10.1093/aje/kwj008
36. Luan Y, Yao Y. The potential role and clinical significance of c-reactive protein in chronic inflammatory and neurodegenerative diseases. *Front Immunol*. 2018; 9: 1302. doi: 10.3389/fimmu.2018.01302
37. Bettcher BM, Wilhelm R, Rigby T, et al. C-reactive protein is related to memory and medial temporal brain volume in older adults. *Brain Behav Immun*. 2012; 26(1): 103-8. doi: 10.1016/j.bbi.2011.07.240
38. Jefferson AL, Massaro JM, Wolf PA, et al. Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study. *Neurology*. 2007; 68(13): 1032-8. doi: 10.1212/01.wnl.0000257815.20548.df
39. Marsland AL, Gianaros PJ, Kuan DC, et al. Brain morphology links systemic inflammation to cognitive function in midlife adults. *Brain Behav Immun*. 2015; 48: 195-204. doi: 10.1016/j.bbi.2015.03.015
40. Satizabal CL, Zhu YC, Mazoyer B, et al. Circulating IL-6 and CRP are associated with MRI findings in the elderly: the 3C-Dijon Study. *Neurology*. 2012; 78(10): 720-7. doi: 10.1212/WNL.0b013e318248e50f
41. Tegeler C, O'Sullivan JL, Bucholtz N, et al. The inflammatory markers CRP, IL-6, and IL-10 are associated with cognitive function—data from the Berlin Aging Study II. *Neurobiol Aging*. 2016; 38: 112-7. doi: 10.1016/j.neurobiolaging.2015.10.039
42. James LM, Georgopoulos AP. Persistent antigen hypothesis: The human leukocyte antigen connection. *J Neurol Neuromed*. 2018; 3(6): 27-31. doi: 10.29245/2572.942X/2018/6.1235
43. Committee on the Development of a Consensus Case Definition for Chronic Multisymptom Illness in 1990-1991 Gulf War Veterans; Board on the Health of Select Populations; Institute of Medicine. *Chronic Multisymptom Illness in Gulf War Veterans: Case Definitions Reexamined*. Washington (DC): National Academies Press (US); 2014. doi: 10.17226/18623

44. Cano P, Klitz W, Mack SJ, et al. Common and well-documented HLA alleles: report of the Ad-Hoc committee of the American society for histocompatibility and immunogenetics. *Hum Immunol.* 2007; 68: 392-417. doi: 10.1016/j.humimm.2007.01.014
45. Glasser MF, Sotiropoulos SN, Wilson JA, et al. The minimal preprocessing pipelines for the human connectome project. *NeuroImage.* 2013; 80: 105-124. doi: 10.1016/j.neuroimage.2013.04.127
46. Kuperberg GR, Broome MR, McGuire PK, et al. Regionally localized thinning of the cerebral cortex in schizophrenia. *Arch Gen Psychiatry.* 2003; 60: 878-888. doi: 10.1001/archpsyc.60.9.878.
47. Salat DH, Buckner RL, Snyder AZ, et al. Thinning of the cerebral cortex in aging. *Cereb Cortex.* 2004; 14: 721-730. doi: 10.1093/cercor/bhh032
48. Rosas HD, Liu AK, Hersch S, et al. Regional and progressive thinning of the cortical ribbon in Huntington's disease. *Neurology.* 2002; 58: 695-701. doi:10.1212/WNL.58.5.695
49. Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis. I. Segmentation and surface reconstruction. *NeuroImage.* 1999; 9: 179-194. doi: 10.1006/nimg.1998.0395.
50. Fischl B, Sereno MI, Dale A. Cortical surface-based analysis II: inflation, flattening, and surface-based coordinate system. *NeuroImage.* 1999; 9: 195-207. doi: 10.1006/nimg.1998.0396
51. Fischl B, Sereno MI, Tootell RBH, et al. High-resolution inter-subject averaging and a coordinate system for the cortical surface. *Hum Brain Mapp.* 1999; 8: 272-284. doi: 10.1002/(SICI)1097-0193(1999)8:4<272::AID-HBM10>3.0.CO;2-4
52. Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic resonance images. *Proc Natl Acad Sci USA.* 2000; 97: 11050-11055. doi: 10.1073/pnas.200033797
53. Desikan RS, Segonne F, Fischl B, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. *NeuroImage.* 2006; 31: 968-980. doi: 10.1016/j.neuroimage.2006.01.021
54. Im K, Lee JM, Lyttelton O, et al. Brain size and cortical structure in the adult human brain. *Cereb Cortex.* 2008; 18(9): 2181-2191. doi: 10.1093/cercor/bhm244
55. Rakic P. Evolution of the neocortex: a perspective from developmental biology. *Nat Rev Neurosci.* 2009; 10(10): 724-735. doi: 10.1038/nrn2719
56. Panizzon MS, Fennema-Notestine C, Eyler LT, et al. Distinct genetic influences on cortical surface area and cortical thickness. *Cereb Cortex.* 2009; 19(11): 2728-2735. doi: 10.1093/cercor/bhp026
57. Hogstrom LJ, Westlye LT, Walhovd KB, et al. The structure of the cerebral cortex across adult life: age-related patterns of surface area, thickness, and gyrification. *Cereb Cortex.* 2013; 23(11): 2521-2530. doi: 10.1093/cercor/bhs231
58. Hutton C, Draganski B, Ashburner J, et al. A comparison between voxel-based cortical thickness and voxel-based morphometry in normal aging. *Neuroimage.* 2009; 48(2): 371-380. doi: 10.1016/j.neuroimage.2009.06.043
59. Dickerson BC, Bakkour A, Salat DH, et al. The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. *Cereb Cortex.* 2009; 19(3): 497-510. doi: 10.1093/cercor/bhn113
60. Lyoo CH, Ryu YH, Lee MS. Topographical distribution of cerebral cortical thinning in patients with mild Parkinson's disease without dementia. *Mov Disord.* 2010; 25(4): 496-499. doi: 10.1002/mds.22975.
61. Li Q, Zhao Y, Chen Z, et al. Meta-analysis of cortical thickness abnormalities in medication-free patients with major depressive disorder. *Neuropsychopharmacology.* 2020; 45: 703-12. doi: 10.1038/s41386-019-0563-9
62. Peterson BS, Warner V, Bansal R, et al. Cortical thinning in persons at increased familial risk for major depression. *Proc Nat Acad Sci.* 2009; 106(15): 6273-6278. doi: 10.1073/pnas.0805311106
63. Liu Y, Li YJ, Luo EP, et al. Cortical thinning in patients with recent onset post-traumatic stress disorder after a single prolonged trauma exposure. *PloS one.* 2012; 7(6): e39025. doi: 10.1371/journal.pone.0039025.
64. Rimol LM, Hartberg CB, Nesvag R, et al. Cortical thickness and subcortical volumes in schizophrenia and bipolar disorder. *Biol Psychiatry.* 2010; 68(1): 41-50. doi: 10.1016/j.biopsych.2010.03.036
65. Tahedl M. Towards individualized cortical thickness assessment for clinical routine. *J Transl Med.* 2020; 18: 151. doi: 10.1186/s12967-020-02317-9
66. Fleischman DA, Arfanakis K, Kelly JF, et al. Regional cortical thinning and systemic inflammation in older persons without dementia. *J Am Geriatr Soc.* 2010; 58(9): 1823. doi: 10.1111/j.1532-5415.2010.03049.x
67. Veit R, Kullmann S, Heni M, et al. Reduced cortical thickness associated with visceral fat and BMI. *NeuroImage: Clinical.* 2014; 6: 307-311. doi: 10.1016/j.nicl.2014.09.013
68. Vidal-Pineiro D, Parker N, Shin J, et al. Cellular correlates of cortical thinning throughout the lifespan. *bioRxiv.* 2020; 585786; doi: 10.1101/585786.
69. Abou-Donia MB. Organophosphorus ester-induced chronic neurotoxicity. *Arch Environ Health.* 2003; 58: 484-497. doi: 10.3200/AEOH.58.8.484-497
70. White RF, Proctor SP, Heeren T, et al. Neuropsychological function in Gulf War Veterans: relationships to self-reported toxicant exposures. *Am J Ind Med.* 2001; 40: 42-54. doi: 10.1002/ajim.1070.
71. Jamal GA, Hansen S, Julu PO. Low level exposures to organophosphorus esters may cause neurotoxicity. *Toxicology.* 2002; 181: 23-33. doi: 10.1016/s0300-483x(02)00447-x.
72. Research Advisory Committee on Gulf War Veterans' Illnesses. *Gulf War Illness and the Health of Gulf War Veterans: Scientific Findings and Recommendations.* Washington, D.C.: U.S. Government Printing Office, November 2008.
73. Hotopf M, David A, Hull L, et al. Role of vaccinations as risk factors for ill health in veterans of the Gulf war: cross-sectional study. *BMJ.* 2000; 320: 1363-1367. doi: 10.1136/bmj.320.7246.1363
74. Unwin C, Blatchley N, Coker W, et al. Health of UK servicemen who served in Persian Gulf War. *Lancet.* 1999; 16: 169-178. doi: 10.1016/S0140-6736(98)11338-7
75. Nass M. The Anthrax Vaccine Program: an analysis of the CDC's recommendations for vaccine use. *Am J Public Health.* 2002; 92(5): 715-21. doi: 10.2105/ajph.92.5.715
76. Institute of Medicine (US). Committee to Review Adverse Effects of Vaccines. Stratton K, Ford A, Rusch E, Clayton EW, Eds.; *Adverse effects of vaccines: evidence and causality.* Washington, DC: National Academies Press; 2011. doi: 10.17226/13164
77. Pajewski NM, Parker SD, Poland GA, et al. The role of HLA-DR-DQ haplotypes in variable antibody responses to anthrax vaccine adsorbed. *Genes Immun.* 2011; 12: 457-465. doi: 10.1038/gene.2011.15
78. Makki K, Froguel P, Wolowczuk I. Adipose tissue in obesity-related inflammation and insulin resistance: cells, cytokines, and chemokines. *ISRN Inflamm.* 2013; 22: 139239. doi: 10.1155/2013/139239
79. Vachharajani V, Granger DN. Adipose tissue: a motor for the inflammation associated with obesity. *IUBMB Life.* 2009; 61(4): 424-30. doi: 10.1002/iub.169.

80. Dursa EK, Barth SK, Schneiderman AI, et al. Physical and mental health status of Gulf War and Gulf Era Veterans: Results from a large population-based epidemiological study. *J Occup Environ Med.* 2016; 58: 41-6. doi: 10.1097/JOM.0000000000000627
81. Coughlin SS, Kang HK, Mahan CM. Selected health conditions among overweight, obese, and non-obese Veterans of the 1991 Gulf War: Results from a survey conducted in 2003-2005. *Open Epidemiol J.* 2011; 4: 140-146. doi: 10.2174/1874297101104010140

### Appendix Cortical ROIs used

1	Left banks of the superior temporal sulcus	35	Right banks of the superior temporal sulcus
2	Left caudal anterior cingulate cortex	36	Right caudal anterior cingulate cortex
3	Left caudal middle frontal gyrus	37	Right caudal middle frontal gyrus
4	Left cuneus cortex	38	Right cuneus cortex
5	Left entorhinal cortex	39	Right entorhinal cortex
6	Left fusiform gyrus	40	Right fusiform gyrus
7	Left inferior parietal cortex	41	Right inferior parietal cortex
8	Left inferior temporal gyrus	42	Right inferior temporal gyrus
9	Left isthmus-cingulate cortex	43	Right isthmus-cingulate cortex
10	Left lateral occipital cortex	44	Right lateral occipital cortex
11	Left lateral orbitofrontal cortex	45	Right lateral orbitofrontal cortex
12	Left lingual gyrus	46	Right lingual gyrus
13	Left medial orbitofrontal cortex	47	Right medial orbitofrontal cortex
14	Left middle temporal gyrus	48	Right middle temporal gyrus
15	Left parahippocampal gyrus	49	Right parahippocampal gyrus
16	Left paracentral lobule	50	Right paracentral lobule
17	Left inferior frontal gyrus pars opercularis	51	Right inferior frontal gyrus pars opercularis
18	Left inferior frontal gyrus pars orbitalis	52	Right inferior frontal gyrus pars orbitalis
19	Left inferior frontal gyrus pars triangularis	53	Right inferior frontal gyrus pars triangularis
20	Left pericalcarine cortex	54	Right pericalcarine cortex
21	Left postcentral gyrus	55	Right postcentral gyrus
22	Left posterior cingulate cortex	56	Right posterior cingulate cortex
23	Left precentral gyrus	57	Right precentral gyrus
24	Left precuneus cortex	58	Right precuneus cortex
25	Left rostral anterior cingulate cortex	59	Right rostral anterior cingulate cortex
26	Left rostral middle frontal gyrus	60	Right rostral middle frontal gyrus
27	Left superior frontal gyrus	61	Right superior frontal gyrus
28	Left superior parietal cortex	62	Right superior parietal cortex
29	Left superior temporal gyrus	63	Right superior temporal gyrus
30	Left supramarginal gyrus	64	Right supramarginal gyrus
31	Left frontal pole	65	Right frontal pole
32	Left temporal pole	66	Right temporal pole
33	Left transverse temporal cortex	67	Right transverse temporal cortex
34	Left insula	68	Right insula